Levothyroxine Timing During Ramadan: Randomized Trials Cannot Pick a Winner
A meta-analysis of five RCTs finds no proven best levothyroxine dosing time during Ramadan, but wide confidence intervals mean the regimens are not shown equivalent.
Summary
People with an underactive thyroid must take levothyroxine on an empty stomach, which is hard during Ramadan, when eating is compressed into the night. This review pooled randomized trials comparing dosing at sunset before the meal, at least 3 hours after the meal, before the predawn meal, and a newer predawn schedule independent of the last meal. Five trials with 712 participants were included. The main measure was change in thyroid-stimulating hormone (TSH), the blood marker doctors use to judge whether the dose is right. No dosing time was shown to be better than another. But the estimates were imprecise and compatible with meaningful differences in either direction, so the schedules cannot be called equivalent. Two trials had high risk of bias, and certainty of evidence was low to very low. This summary is based on the abstract only.
Detailed Summary
Thyroid hormone status shapes energy, metabolism, cholesterol, heart rhythm and cognition, so keeping TSH in range matters for healthspan in the many adults, especially older ones, who take levothyroxine. The drug is absorbed best on an empty stomach, which clashes with the short nightly eating window of Ramadan.
This systematic review and meta-analysis, registered in PROSPERO and conducted under PRISMA 2020, searched PubMed, Scopus and Google Scholar for randomized trials. Eligible trials compared two or more levothyroxine dosing times during Ramadan in adults with primary hypothyroidism or prior total thyroidectomy. The times were pre-iftar (at sunset), post-iftar (at least 3 hours after the meal), pre-suhoor (before the predawn meal) and a predawn schedule independent of the last meal. The primary outcome was change in TSH from before to after Ramadan.
Five trials with 712 participants were included. For pre-iftar versus pre-suhoor (2 trials, n = 149), the mean difference in TSH change was -0.61 mIU/l, with a very wide random-effects interval of -6.67 to 5.45. Single trials found pre-iftar versus post-iftar 0.10 mIU/l (n = 65), post-iftar versus pre-suhoor -2.10 mIU/l (n = 56) and pre-iftar versus predawn -0.33 mIU/l (n = 302). All intervals included zero. Results held across assumed correlations and after adding converted data from another trial.
The randomized evidence does not show that any single timing is superior. Because the intervals are wide enough to include clinically important differences in either direction, the regimens also cannot be called equivalent. Adherence differed between regimens in individual trials, but how much it matters relative to timing was not established.
Caveats: two trials had high risk of bias, certainty was low to very low for every comparison, and two trials reported TSH only as percentiles or box plots, so they could not be pooled. This summary rests on the abstract alone. The review addresses a surrogate marker, TSH, not symptoms or clinical outcomes.
Key Findings
- Five RCTs (712 participants) compared levothyroxine timing during Ramadan; none showed a dosing time clearly superior for TSH change.
- Pre-iftar vs pre-suhoor (2 RCTs, n=149): TSH change difference -0.61 mIU/l, 95% CI -6.67 to 5.45.
- Pre-iftar vs predawn (1 trial, n=302): difference -0.33 mIU/l (95% CI -1.14 to 0.48), the most precise estimate.
- Certainty of evidence was low to very low, and two trials had high risk of bias.
- Wide intervals mean the regimens are not proven equivalent; adherence differed between regimens, but its role was not established.
Methodology
Systematic review and meta-analysis of RCTs following PRISMA 2020, registered in PROSPERO. Mean differences in TSH change were pooled with random-effects REML and Hartung-Knapp intervals when at least two trials shared a comparison; other data were synthesized narratively. Bias was assessed with RoB 2 and certainty with GRADE.
Study Limitations
The summary is based on the abstract only. Few trials, small samples for most comparisons, high risk of bias in two trials and low to very low certainty limit conclusions, and several comparisons rest on a single trial. TSH is a surrogate endpoint, and adherence was not objectively measured.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
